Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL-601
- Development stage
- Preclinical
- Lead developer
- BioQingLam
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Transdermal
01
Overview
QL-601 is a recombinant protein vaccine candidate developed by BioQingLam for the prevention of influenza. The vaccine is designed for transdermal administration using the company's proprietary soluble microneedle patch technology. This delivery platform aims to provide a painless alternative to traditional injections while potentially enhancing the immune response through the targeting of antigen-presenting cells in the skin. QL-601 targets influenza antigens to elicit protective immunity against the flu. It is currently being evaluated in investigator-initiated trials (IIT) as part of BioQingLam's pipeline of microneedle-delivered therapeutics.
Beyond the preview
Go deeper on QL-601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL-601.